Clinical studies of antisense oligonucleotides for cancer therapy

Methods Mol Med. 2005;106:85-111. doi: 10.1385/1-59259-854-4:085.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Cyclic AMP-Dependent Protein Kinases / genetics
  • DNA Modification Methylases / genetics
  • Genes, p53
  • Genes, ras
  • Humans
  • Neoplasms / therapy*
  • Oligonucleotides, Antisense / therapeutic use*
  • Protein Kinase C / genetics
  • Protein Kinase C-alpha
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Proto-Oncogene Proteins c-myb / genetics
  • Proto-Oncogene Proteins c-raf / genetics
  • Ribonucleotide Reductases / genetics

Substances

  • Antineoplastic Agents
  • Oligonucleotides, Antisense
  • Proto-Oncogene Proteins c-bcl-2
  • Proto-Oncogene Proteins c-myb
  • Ribonucleotide Reductases
  • DNA Modification Methylases
  • Proto-Oncogene Proteins c-raf
  • Cyclic AMP-Dependent Protein Kinases
  • PRKCA protein, human
  • Protein Kinase C
  • Protein Kinase C-alpha